Validating The Prognostic Significance Of FCRL2 In Predicting IGHV Mutation Status, Clinical Disease Progression, and Survival In CLL
Li FJ, Cantor AB, Shakhmatov MA, et al.
Key Points:
Experiments conducted lend further support to value of Fc receptor-like 2 (FCRL2) as prognostic biomarker in CLL patients
High levels of FCRL2 preferentially expressed by IGHV-mutated CLL cells, and strongly correlates with favorable progression free survival and overall survival rates
A novel monoclonal antibody (3E11) also identified for future studies of FCRL2 in CLL
Implications:
- IGHV mutational status and level of FCRL2 expression together could be more powerful predictors of survival outcomes in CLL patients than CD38 and ZAP70 expression
View the original abstract on the ASH website.
